Eli Lilly CEO on weight loss drugs outlook: Our top priority is making more product

NIH Director: Alzheimer's a huge priority for us

Eli Lilly's stock jumps on promising weight-loss drug

Eli Lilly stock tumbles 10% after drug giant misses estimates and slashes profit guidance

Cramer: Eli Lilly's share price recovery symbolizes this market's attitude

Eli Lilly CEO on the company's Q2 earnings and core business performance

Analyst breaks down what is behind Eli Lilly's Q3 earnings miss